Patents Assigned to Pacific Northwest Research Foundation
  • Patent number: 6111255
    Abstract: Methods of screening for a tumor or tumor progression to the metastatic state are provided. The screening methods are based on the characterization of DNA by principal components analysis of spectral data yielded by Fourier transform-infrared spectroscopy of DNA samples. The methods are applicable to a wide variety of DNA samples and cancer types.
    Type: Grant
    Filed: June 23, 1999
    Date of Patent: August 29, 2000
    Assignee: Pacific Northwest Research Foundation
    Inventor: Donald C. Malins
  • Patent number: 5945675
    Abstract: Methods of screening for a tumor or tumor progression to the metastatic state are a provided. The screening methods are based on the characterization of DNA by principal components analysis of spectral data yielded by Fourier transform-infrared spectroscopy of DNA samples. The methods are applicable to a wide variety of DNA samples and cancer types.
    Type: Grant
    Filed: March 17, 1997
    Date of Patent: August 31, 1999
    Assignee: Pacific Northwest Research Foundation
    Inventor: Donald C. Malins
  • Patent number: 5665553
    Abstract: Methods for determining the genotoxic or carcinogenic status of a subject by analyzing the cellular redox potential of a test specimen where an increased risk of, or presence of, genotoxic injury or cancer is indicated when the cellular redox potential favors oxidatively derived modified nucleotide bases. A sensitive method is disclosed wherein DNA is isolated from a test specimen obtained from a test subject and assayed for modified nucleotide bases that have formed either stable reductively formed derivatives or stable oxidatively formed derivatives. By identifying and comparing those modified nucleotide bases derived via reductive pathways to those modified nucleotide bases derived via oxidative patwhays, a determination as to the cancer status of the test specimen can be made wherein a greater cancerous state exists when the ratio between the two species of modified nucleotide bases indicates that oxidatively formed derivative are favored over reductively formed derivatives.
    Type: Grant
    Filed: October 26, 1995
    Date of Patent: September 9, 1997
    Assignee: Pacific Northwest Research Foundation
    Inventor: Donald C. Malins
  • Patent number: 5601981
    Abstract: Methods for determining the genotoxic or carcinogenic status of a subject by analyzing the cellular redox potential of a test specimen where an increased risk of, or presence of, genotoxic injury or cancer is indicated when the cellular redox potential favors oxidatively derived modified nucleotide bases. A sensitive method is disclosed wherein DNA is isolated from a test specimen obtained from a test subject and assayed for modified nucleotide bases that have formed either stable reductively formed derivatives or stable oxidatively formed derivatives. By identifying and comparing those modified nucleotide bases derived via reductive pathways to those modified nucleotide bases derived via oxidative pathways, a determination as to the cancer status of the test specimen can be made wherein a greater cancerous state exists when the ratio between the two species of modified nucleotide bases indicates that oxidatively formed derivative are favored over reductively formed derivatives.
    Type: Grant
    Filed: October 6, 1994
    Date of Patent: February 11, 1997
    Assignee: Pacific Northwest Research Foundation
    Inventor: Donald C. Malins
  • Patent number: 4971905
    Abstract: A method for diagnostic or prognostic monitoring of premalignant or malignant conditions of human secretory epithelia, particularly colonic epithelia, by determining the extent of expression of a .beta.1-3N-acetylglucosaminyltransferase is described. Associated with the expression of a wide variety of carbohydrate antigens in adenocarcinomas is the induction of .beta.1-3N-acetylglucosaminyltransferase in epithelial cells. This enzyme is not found in normal, healthy adult colonic epithelial cells and thus indicates a novel and potentially sensitive method for screening the disease status of individuals.
    Type: Grant
    Filed: August 11, 1987
    Date of Patent: November 20, 1990
    Assignee: Pacific Northwest Research Foundation
    Inventor: Eric H. Holmes